A Study of Tarlatamab in Combination With AB248 in People With Small-Cell Lung Cancer

Full Title

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination with AB248 in Participants with Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Mark Awad’s office at 646-608-4371.

Protocol
26-055
Phase
Phase I (phase 1)
Disease Status
Relapsed or Refractory
Investigator
Mark Awad
Co-Investigators
Charles M. Rudin
Diseases
Lung Cancer › Lung Cancer, Small Cell
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07037758
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description